logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Kite Pharma's CAR-T Therapy Passed the Test with High Grades

We keep reiterating that CAR-T cancer immunotherapy was created to stay. More frequent updates about the CAR-T approach further solidified our conviction. Almost every week we are getting news eliminating layer by layer of the true problems about CAR-T therapy...

Read More

March 2, 2017

0

Osteoporosis: Romosozumab from Amgen Succeeds in Preventing Bone Fracture

AMGEN AND OSTEOPOROSIS Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study of  Romosozumab In Postmenopausal Women With Osteoporosis The FRAME Study Met All Primary Endpoints by Reducing the Incidence of New Vertebral Fracture Through 12 and...

Read More

February 22, 2016

0

Why Would a Specific Rheumatoid Arthritis Drug Treat Aggressive Cancers? Read Also: Other Important News

An approved rheumatoid arthritis drug developed and sold by Sanofi could become a new treatment for aggressive cancers. The news came in a Mount Sinai press release announcing that researchers have discovered that a rheumatoid arthritis drug can block a...

Read More

March 3, 2017

0

Ionis Drug Volanesorsen's Reward Outweighs the Mitigated Risk

Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals (IONS) , announced positive results from the pivotal Phase 3 APPROACH study of the drug volanesorsen . The results demonstrate that the drug met its primary endpoint of reducing triglyceride levels...

Read More

March 8, 2017

0

Nektar: Killing Pain While Fighting Addiction. Stock is Up 28 Percent

Nektar Therapeutics (NKTR) announced positive results from the SUMMIT-07 Phase 3 efficacy study of its painkiller drug known as NKTR-181 . The drug, which is a first-in-class opioid analgesic is a new chemical entity (NCE). It is the first full...

Read More

March 20, 2017

0

Amgen's Underrated Great News. Array Pharma's Smart Move

AMGEN Amgen’s ( AMGN ) cholesterol lowering drug Repatha is the only drug that has demonstrated protection against heart attack and stroke in high risk patients. Prior to the FOURIER trial, which confirmed the effect of Repatha in lowering cardiovascular...

Read More

March 21, 2017

0

CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY

Everybody knows Bristol-Myers Squibb (BMY) , but just a few may know anything about CytomX Therapeutics (CTMX ) , or about its Probody Program. CytomX is a small, develop-ment-stage firm that created platform known as the Probody Program, which leads...

Read More

March 23, 2017

0

Agenus Reform and Downsizing. Innoviva's Voting Dilemma

Agenus (AGEN ) is reorganizing its business and operations. The reasons the firm cited comprise sharpening of its focus on clinical development of its two checkpoint inhibitor antibodies and vaccine program. Among others are: - Closing its Basel site and...

Read More

March 30, 2017

0

Advancements in Cancer Immunotherapy. See Also: A Small Firm with Promising News

CANCER IMMUNOTHERAPY Nonstop Improvements and Nonstop Discoveries Checkpoint inhibitors and CAR-T immunotherapy are created to stay and succeed and change the way cancer has been treated for decades. The reason is that the successful results from some early attempts to...

Read More

April 8, 2017

0

Why Illumina Might Be Offering a Lucrative Investment Opportunity

Illumina Showing 6% revenue increase over the same quarter last year, Q1 2016, was not enough as  Illumina (ILMN)  missed analysts’ expectations and its own projections regarding its revenues. Prior to the announcement of its Q1 results, the giant gene sequencing...

Read More

April 21, 2016

0

  • Previous
  • 1
  • 2
  • ...
  • 11
  • 12
  • 13
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy